Information Provided By:
Fly News Breaks for June 6, 2017
ACOR
Jun 6, 2017 | 08:34 EDT
Leerink analyst Paul Matteis believes Acorda Therapeutics' full Phase III results for CVT-301 support his 90% odds of FDA approval. He expects the product to be approved in the middle of next year and models for $278M of sales in 2022. The analyst keeps a Market Perform rating on Acorda shares.
News For ACOR From the Last 2 Days
There are no results for your query ACOR